

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

GILGAMESH PHARMACEUTICALS, INC.,
Petitioner,

v.

ENVERIC BIOSCIENCES CANADA, INC.,
Patent Owner.

PGR2025-00076
Patent 12,138,276

PETITIONER'S UPDATED MANDATORY NOTICES

Pursuant to 37 C.F.R. § 42.8(a)(3), Petitioner hereby provides the following updates to its mandatory notices as set forth in Paper No. 1. Such information is being filed with the Board within 21 days of a change of information and is thereby timely.

REAL PARTY-IN-INTEREST UNDER 37 C.F.R. § 42.8(B)(1)

On October 17, 2025, Petitioner Gilgamesh Pharmaceuticals, Inc. became a wholly owned subsidiary of Warka Intermediate LLC, which is in turn a wholly owned subsidiary of AbbVie Inc. In accordance with 37 C.F.R. § 42.8(b)(1), Petitioner identifies Warka Intermediate LLC and AbbVie Inc. as real parties-in-interest to this proceeding.

Dated: November 7, 2025

Respectfully submitted,

/Peter I. Bernstein/

Peter I. Bernstein (Reg. No. 43,497)

pibernstein@ssmp.com

SCULLY SCOTT MURPHY & PRESSER, P.C.

Lead Counsel for Petitioner

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of the foregoing **PETITIONER'S
UPDATED MANDATORY NOTICES** was served on November 7, 2025, via email directed to
counsel of record for the Patent Owner at the following address:

Kristi L.R. Sawert
Michael Kaine
Casey Kraning
PGR60676-0002PS1@fr.com

Dated: November 7, 2025

By: /Peter I. Bernstein/
Peter I. Bernstein (43,497)
SCULLY SCOTT MURPHY & PRESSER, P.C.